Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CASI Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CASI
Nasdaq
2836
www.casipharmaceuticals.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CASI Pharmaceuticals, Inc.
This CASI Pharmaceuticals Insider Increased Their Holding By 65% Last Year
- Feb 6th, 2025 1:44 pm
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
- Jan 6th, 2025 1:00 pm
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
- Nov 17th, 2024 12:09 pm
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
- Nov 15th, 2024 1:00 pm
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
- Oct 24th, 2024 12:00 pm
CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week
- Sep 26th, 2024 5:18 pm
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
- Sep 4th, 2024 12:00 pm
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
- Aug 16th, 2024 12:00 pm
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
- Jul 19th, 2024 9:30 pm
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
- Jul 8th, 2024 11:30 am
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
- Jun 27th, 2024 1:42 pm
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company
- Jun 26th, 2024 8:15 pm
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
- Jun 26th, 2024 8:10 pm
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
- May 15th, 2024 12:00 pm
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
- May 14th, 2024 12:00 pm
Analysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI)
- Apr 24th, 2024 10:42 am
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
- Mar 28th, 2024 11:00 am
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
- Mar 5th, 2024 12:00 pm
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
- Feb 16th, 2024 12:00 pm
Scroll